Tumour cell-secreted factors skew infiltrating immune cells towards a tumour-supporting phenotype, expressing pro-tumourigenic mediators. However, the influence of lipocalin-2 (Lcn2) in the tumour microenvironment on the metastatic cascade is still not clearly defined. Here, we explored the role of stroma-derived, especially macrophage-released, Lcn2 in breast cancer progression. Knockdown studies and neutralizing antibody approaches showed that Lcn2 contributes to the early events of metastasis in vitro. The release of Lcn2 from macrophages induced an epithelial-to-mesenchymal transition program in MCF-7 breast cancer cells and enhanced local migration as well as invasion into the extracellular matrix using a 3D-spheroid model. Moreover, a global Lcn2-deficiency attenuated breast cancer metastasis both in the MMTV-PyMT breast cancer model and in a xenograft model inoculating MCF-7 cells pre-treated with supernatants from wild type and Lcn2-knockdown macrophages. To dissect the role of stroma-derived Lcn2, we employed an orthotopic mammary tumour mouse model. Implantation of wild type PyMT tumour cells into Lcn2-lacking mice left primary mammary tumour formation unaltered, but specifically reduced tumour cell dissemination into the lung. We conclude that stroma-secreted Lcn2 promotes metastasis in vitro and in vivo, thereby contributing to tumour progression. Our study highlights the tumourigenic potential of stroma-released Lcn2 and suggests Lcn2 as putative therapeutic target.
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Introduction Lipocalin-2 (Lcn2) is a 25 kDa glycoprotein of the lipocalin superfamiliy [1, 2] that plays a pivotal role during bacterial infections [3] , kidney regeneration [4], sepsis [5] , and cancer [6] . Regarding tumour progression, several studies indicate that Lcn2 expression correlates with poor prognosis [7] [8] [9] . Additionally, Lcn2 serves as a prognostic and diagnostic marker, because elevated levels of Lcn2 are detected in the urine of cancer patients [9] . Lcn2 displays pleiotropic functions and promotes proliferation, survival, differentiation, and migration [10] , thus rendering Lcn2 a putative mediator of tumour development. It was previously reported that Lcn2 promotes lung metastasis of murine breast cancer cells after injecting Lcn2-overexpressing 4T1 cells [11] . Lcn2 has been proposed to promote early events of tumour metastasis. On one side, tumour-supporting effects of Lcn2 can be explained by stabilizing gelatinase B (MMP-9) [12] , thereby enhancing degradation of the extracellular matrix and tumour cell dissemination [13, 14] .
On the other side, Lcn2 induces epithelial-to-mesenchymal-transition (EMT). Specifically, overexpression of Lcn2 in MCF-7 breast cancer cells provokes EMT by reducing Ecadherin and increasing vimentin and fibronectin [9] . In contrast, the knockdown of Lcn2 in MDA-MB-231 breast cancer cells reverses EMT, associated with reduced tumour growth and metastasis [9] . In line with this, we recently described that Lcn2 conveys EMT characteristics to A375 melanoma cells, enhancing migration and invasion [15] . Moreover, the use of mouse mammary tumour models showed that Lcn2 -/-mice developed significantly fewer tumours, but differences in metastasis are still controversially discussed [16] [17] [18] . Importantly, the role of Lcn2 was mainly examined in tumour cells, whereas the possibility that Lcn2 is provided by tumour infiltrating immune cells, such as neutrophils or macrophages, was not taken into account so far.
Chronic inflammation and an impaired immune response provoke outgrowth of transformed cells and tumour progression [19] . Tumour-associated immune cells acquire a This article is protected by copyright. All rights reserved. 
RNA extraction and Reverse Transcription-quantitative PCR (RT-qPCR)
RNA extraction, reverse transcription and qPCR was performed as previously described 
Transendothelial migration assay
MCF-7 cells were stimulated with 1 µg/ml Lcn2 or MCM for 4 days and marked with Cell
Tracker green. HPMEC (1 x 10 5 ) were seeded into fibronectin-coated Transwell inserts of a 24-well plate (Greiner Bio-One, Frickenhausen, Germany) and were grown to confluence. MCF-7 cells (5 x 10 4 ) were added into each insert. After 24 h, cells were washed and fixed with 4% PFA. Five fields per well were counted and the mean was calculated for each group. At least three independent experiments using triplicates were performed.
Cell migration assay
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MCF-7 cells were transfected either with siSLC22A17 or scrambled control siRNA (scRNA) and cell migration assay was performed as described previously [24] .
Measurement of the scratch area was accomplished using ImageJ software. The 0 h value was normalized to the 24 h value of each group. The relative migration rate defines the mean value of at least three independent experiments using triplicates.
Spheroid invasion assay
MCF-7 spheroids were generated in 1.5% agarose-coated 96-well-plates (Greiner BioOne). Spheroids were stimulated with scRNA MCM and siLcn2 MCM every 3 days for 2 weeks and subsequently embedded in a collagen I matrix for 7 days. 3 pictures were taken of each spheroid from each group (triplicates) from at least three independent experiments. Distance of invasion from the spheroid border into the collagen I matrix was measured using Axiovision software (Zeiss).
Statistical analysis
Each experiment was performed at least three times. The p values were calculated using Student's t-test or one-way ANOVA, and considered significant at *p<0.05, **p<0.01, ***p<0.001.
Accepted Article

Results
Lcn2 ablation delays tumour growth and metastasis of PyMT breast tumours
We analysed the impact of Lcn2 in the spontaneous PyMT breast cancer model, where all female mice developed a tumour within 150 days in at least one mammary gland. We detected a significantly delay of tumour growth in Lcn2 -/-PyMT mice starting at week ~ 16, whereas tumour growth in wt PyMT mice was already detected at week ~ 12 (Fig. 1A) .
Accordingly, Lcn2 -/-PyMT mice reached the end point of 1.5 cm tumour diameter at later times (week ~ 23), compared to wt PyMT mice that were sacrificed at week ~ 19 (Fig. 1B) .
In order to define the extent of overall tumour development, we chose 18 weeks, a timepoint when all mice showed tumour burden. Lcn2 -/-PyMT mice had smaller tumours and showed more mammary glands without tumour burden compared to wt PyMT mice (Fig.   1C ), but the tumour diameter and number of glands with tumours did not significantly differ at the end point of 1.5 cm (Fig. 1D) . Interestingly, we saw significant differences in the number of metastases-bearing mice comparing wt and Lcn2 -/-groups at sacrifice. The percentage of mice developing lung metastases was significantly lower in the Lcn2 -/-group compared to the wt group ( Fig. 1E-F ).
Lcn2 induces metastatic spread in vitro
We previously described that not only tumour cells, but also macrophages express Lcn2 after exposure to apoptotic tumour cell supernatants [4] . In the context of cancer, we reported that TAM-released Lcn2 supports tumour growth [24] , but the impact on metastasis was not investigated so far. Therefore, we generated macrophage-conditioned medium containing Lcn2 (MCM) by stimulation of primary human macrophages with apoptotic tumour cell supernatants (ACM) and used in vitro lung metastasis assays to characterise the ability of macrophage-released Lcn2 to promote the metastatic tumour cell phenotype. Most interestingly, ACM-stimulated macrophages secreted significantly
Accepted Article higher levels of Lcn2 compared to tumour cells (Fig. S1A and S1B ). Control macrophages were treated with scRNA in order to generate supernatants containing Lcn2 (scRNA MCM) (Fig. S2) . MCF-7 spheroids were stimulated with siLcn2 MCM, scRNA MCM, or left in normal growth medium (control) for ten days. Subsequently, spheroids were embedded into a collagen I matrix for additional seven days to allow invasion into the matrix. ScRNA MCM-treated spheroids showed significantly enhanced invasion into the collagen I matrix, whereas siLcn2 MCM-stimulated spheroids displayed reduced invasion (Fig. 2D) .
TAM-released Lcn2 facilitates lung colonization in vivo
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As we had established that macrophage-derived Lcn2 induces metastatic spread in vitro, we wondered if these effects can be transferred to a breast cancer in vivo model.
Therefore, we employed a xenograft model using MCF-7 cells that were pre-treated with scRNA MCM and siLcn2 MCM for 3 days. Our analysis of the tumour volume did not detect differences in tumour growth (Fig. 3A) . Also, the weight of tumours at sacrifice was equivalent (Fig. 3B) . Interestingly, the dissemination of implanted MCF-7 tumour cells to the lungs was significantly decreased by siLcn2 MCM-pre-treatment (Fig. 3C) .
Furthermore, histological analysis was performed in order to detect ER-positive proliferating (Ki-67-positive) tumour cell colonies (Fig. 3D) . Representative pictures are shown for the co-localization of ER-and Ki-67-positive metastatic lesions. These data support the hypothesis that macrophage-derived Lcn2 increases the invasiveness of breast cancer cells, thereby facilitating metastatic spread.
Macrophage-derived Lcn2 induces EMT through its specific receptor SLC22A17
Since the higher migratory and invasive character of tumour cells is often associated with the transition from an epithelial to a mesenchymal state, the process of EMT plays an integral role in cancer metastasis. Therefore, we reasoned that macrophage-derived Lcn2 promotes EMT in breast cancer cells. MCM elicited a decrease in transcript abundance for the epithelial marker E-cadherin (CDH1) (Fig. 4A ) and an increase of the mesenchymal marker N-cadherin (CDH2) (Fig. 4B ) in human MCF-7 breast cancer cells. This effect was significantly attenuated by neutralizing Lcn2, while addition of the IgG control antibody was without effect. To exclude potential cell-specific effects, we verified changes in E-cadherin and N-cadherin mRNA abundance in response to MCM in T47D breast cancer cells, A549 lung carcinoma cells, and HUH7 hepatocellular cells (Fig. S3) . In all cell lines tested, MCM decreased E-cadherin and increased N-cadherin mRNA expression. These changes were significantly reversed by neutralizing Lcn2. Analysis of EMT-related transcription factors showed the potential involvement of ZEB1, whereas SNAI1 was not affected (Fig. S4 ).
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Neither Slug (SNAI2) nor Twist (TWIST1) transcripts could be detected. To explore the role of the specific Lcn2 receptor (SLC22A17) in transmitting EMT promoting effects on tumour cells, we performed a transient siRNA knockdown in MCF-7 cells (Fig. S5) . Both, control (scRNA) and SLC22A17-downregulated tumour cells were stimulated with MCM for 24 h and the abundance of mRNA encoding the EMT markers E-cadherin (Fig. 4C) and Ncadherin (Fig. 4D) were measured by RT-qPCR. The previously observed impact of MCM on EMT marker expression was significantly reversed by the knockdown of SLC22A17.
Since EMT correlates with increased migration rates, we explored if the knockdown of SLC22A17 affected tumour cell migration. Indeed, the knockdown of SLC22A17 impaired tumour cell migration (Fig. 4E ). Quantification showed a significantly reduced migration rate in siSLC22A17 knockdown cells (Fig. 4F ).
Stroma-derived Lcn2 induces breast cancer cell dissemination into the lung
In order to evaluate the impact of stroma-derived Lcn-2 on tumour growth and metastasis, we established an orthotopic breast cancer model. We used both wt and Lcn2 -/-PyMT mice as tumour cell donors and Lcn2 +/+ and Lcn2 -/-C57BL/6 mice as recipients. A schematic picture of the model is shown in Figure 5A . Implantation of Lcn2 -/-tumour cells into Lcn2 +/+ and Lcn2 -/-mice allowed us to analyse stroma-derived Lcn2 effects on tumour growth and metastasis. In addition, the comparison of implanted wt and Lcn2 -/-tumour cells allowed us to determine tumour cell-derived Lcn2 effects. We could not detect any differences in tumour development between Lcn2 +/+ and Lcn2 -/-recipients, neither for Lcn2-competent donors (Fig. 5B) , nor for Lcn2-deficient donors (Fig. 5C) . Furthermore, the tumour weight at sacrifice did not differ significantly, suggesting that stroma-derived Lcn2
is not important for primary tumour growth ( Fig. 5D-E) . In order to detect lung metastases derived from implanted PyMT-positive tumour cells, we performed immunofluorescence using a PyMT specific antibody in combination with staining of proliferating tumour cells using Ki-67. Representative pictures show an efficient co-localization of PyMT-and Ki-67-This article is protected by copyright. All rights reserved.
Accepted Article positive tumour cells (Fig. 5F ). Quantification of double-positive tumour cells showed that the injection of wt tumour cells into Lcn2 -/-recipient mice elicited a significant decrease in the number of disseminated Ki-67-positive PyMT tumour cells within the lung (Fig. 5G) .
However, implantation of Lcn2-deficient tumour cells resulted in a slight, but not significant reduction of the number of disseminated tumour cells in Lcn2 -/-recipient mice compared to wt recipients (Fig. 5H) . Remarkably, the Lcn2 -/-recipient showing decreased tumour cell dissemination, had a reduced number of E-cadherin low /N-cadherin high tumour cells (Fig.   6A ). The in vivo situation in the orthotopic model was corroborated in the PyMT model, where Lcn2-deficient PyMT mice revealed a reduced number of E-cadherin low /Ncadherin high -tumour cells (Fig. 6B) . Our results suggest that stroma-derived Lcn2 enhances metastatic spread by promoting different steps of the metastatic cascade, such as adhesion, transendothelial migration, invasion, and EMT (Fig. 6C ).
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Discussion
The present study reveals a previously unknown function of stroma-derived Lcn2 on breast However, we previously showed that macrophage-released Lcn2 enhanced the proliferative capacity of MCF-7 breast cancer cells in vitro [24] . To prove the impact of macrophage-derived Lcn2 on breast cancer progression in vivo, we used a xenograft model involving MCF-7 cells pre-treated with macrophage supernatants and an orthotopic mammary tumour model. Neither the xenograft (Fig. 3A-B) , nor the orthotopic model (5B-E) displayed differences in primary tumour growth. In the present study, we also checked This article is protected by copyright. All rights reserved.
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for tumour growth, both in a 3D tumour spheroid model and in 2D cell culture, but failed to detect differences in primary growth characteristics in the complex 3D system, whereas the 2D cultured responded as described before [24] . shown to support tumour progression by stabilizing MMP-9, thereby facilitating ECM degradation [12, 14] . Apparently, tumour cell-derived Lcn2 as well as stroma-derived Lcn2 might be important players during the metastatic spread. However, our orthotopic tumour model suggests that predominantly stroma-derived Lcn2 induces metastasis by promoting tumour cell dissemination into the lung. Therefore we questioned whether this results from the induction of EMT in tumour cells. In fact, we showed that macrophage-derived Lcn2
induces EMT in MCF-7 breast cancer cells by reducing the epithelial marker E-cadherin and inducing the mesenchymal marker N-cadherin (Fig. 4A-D) . Importantly, we observed a more robust and consistent Lcn2-induced expression of N-cadherin rather than repression This article is protected by copyright. All rights reserved.
of E-cadherin in vitro. However, it is important to note that EMT usually is not a complete transition but rather a transient and reversible process, since many tumours might also coexpress both cadherins, illustrating thereby their plasticity [32] . Nevertheless, it is speculated that a proportion of fully acquired EMT-cells are required for effective invasion through the ECM, thereby opening the way for non-or transient-EMT-cells to enter the bloodstream and to spread into distant organs.
In summary, we propose that stroma-derived Lcn2 enhances the malignant characteristics of breast cancer cells. Our studies underscore the significance of stroma- 
